Intellia Therapeutics (NTLA) PT Lowered to $50 at BMO Capital; 'Strategic Plan Unsurprising, May Disappoint Investors'
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $50.00 (from $70.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
